Press Releases
May. 12, 2011 biOasis Initiates Transcend Vector Program Targeting Treatments for CNS Symptoms of Lysosomal Storage Disorders
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V.BTI) announced today the initiation of its first Transcend therapeutic development program directed towards developing treatments for the neurological effects of lysosomal storage disorders (“LSD”). This strategic decision is based on recently announced results from the National Research Council of Canada demonstrating that intravenously administered Transcend is delivered… Read more »
May. 3, 2011 biOasis Receives Verification That Transcend Localizes To a Number of Cell Types in the Brain
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) has received further experimental results from research performed on behalf of the Company by the National Research Council of Canada (“NRC”). This work was performed for the purpose of providing independent confirmation of results generated in prior work conducted by the Company. As reported previously, the… Read more »
Apr. 19, 2011 biOasis Adds MarketSmart Communications Inc. to Investor Relations Team
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) is pleased to announce it has entered into a consulting agreement (“Agreement”) for MarketSmart Communications Inc (“MarketSmart”) to provide investor relations services to the Company. MarketSmart was established in 2002 and President, Maria Da Silva has worked with many TSX Venture Exchange companies to assist in… Read more »
Apr. 15, 2011 biOasis Receives Significant Independent Results From its Transcend Program
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) has received experimental results from research performed on behalf of the Company by the National Research Council of Canada (“NRC”). This work was performed for the purpose of providing independent confirmation of results generated in prior work conducted by the Company. The NRC study used the… Read more »
Apr. 14, 2011 biOasis Director Resigns
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) announces that Mr. George Sanders has resigned from the board of directors for personal reasons. Mr Sanders has been a member of the board since February 14, 2007. “We would like to thank George for his valuable contribution and service on the board of directors of… Read more »
Mar. 25, 2011 biOasis Poster Being Presented at 17th Annual Blood-Brain Barrier Consortium Meeting
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX,V:BTI) announces it is presenting Friday, March 25, 2011 a poster titled “A new Carrier for Delivery of Therapeutic Compounds Across the BBB for the Treatment of Brain Diseases” at the 17th annual Blood-Brain Barrier Consortium meeting held in collaboration with the International Brain Barriers Society (IBBS) being… Read more »
Mar. 1, 2011 CognitestTM – Diagnostic Blood Test for Alzheimer’s disease – Milestone Attained
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX,V:BTI) is pleased to announce the completion of a project intended to produce proprietary monoclonal antibodies (mAbs) for its CognitestTM blood test for Alzheimer’s disease. Highlights: Simple, easy to use diagnostic blood test for Alzheimer’s ready for clinical testing Human sample testing starting and to run over the… Read more »
Feb. 24, 2011 Shareholder Update – 2010 Year in Review
Vancouver, British Columbia–(Business Wire)– The management of biOasis Technologies Inc. (TSX.V: BTI) is pleased to provide this year in review update to highlight the corporate accomplishments made in 2010. Highlights: Significantly higher concentrations of p97 successfully transported across the Blood-Brain Barrier Commercial development of Cognitest™ (Alzheimer’s disease blood test) underway $1,029,287 private placement completed Dr.… Read more »